Last reviewed 2026-04-22 · How we verify

Docetaxel+ carboplatin+ trastuzumab + patuzumab

Docetaxel+ carboplatin+ trastuzumab + patuzumab is a Combination chemotherapy with HER2-targeted monoclonal antibodies Small molecule drug developed by Henan Cancer Hospital. It is currently in Phase 3 development for HER2-positive breast cancer (metastatic or locally advanced). Also known as: TCbHP regimen group.

This combination uses a taxane chemotherapy agent with platinum-based chemotherapy alongside two HER2-targeted monoclonal antibodies to inhibit cancer cell division and HER2-mediated growth signaling.

This combination uses a taxane chemotherapy agent with platinum-based chemotherapy alongside two HER2-targeted monoclonal antibodies to inhibit cancer cell division and HER2-mediated growth signaling. Used for HER2-positive breast cancer (metastatic or locally advanced).

At a glance

Mechanism of action

Docetaxel is a microtubule-stabilizing taxane that prevents cell division; carboplatin is a platinum agent causing DNA damage; trastuzumab (Herceptin) is a HER2-directed monoclonal antibody blocking HER2 signaling; pertuzumab (Perjeta) is a HER2 dimerization inhibitor that prevents HER2 from pairing with other receptors. Together, these agents provide complementary cytotoxic and targeted mechanisms against HER2-positive cancers.

Approved indications

• HER2-positive breast cancer (metastatic or locally advanced)

Common side effects

• Neutropenia
• Anemia
• Thrombocytopenia
• Neuropathy
• Nausea/vomiting
• Fatigue
• Diarrhea
• Cardiac dysfunction
• Hypersensitivity reactions

Key clinical trials

• Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer (PHASE3)
• Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC (PHASE2)
• A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Docetaxel+ carboplatin+ trastuzumab + patuzumab CI brief — competitive landscape report
• Docetaxel+ carboplatin+ trastuzumab + patuzumab updates RSS · CI watch RSS
• Henan Cancer Hospital portfolio CI

Frequently asked questions about Docetaxel+ carboplatin+ trastuzumab + patuzumab

Related

• Drug class: All Combination chemotherapy with HER2-targeted monoclonal antibodies drugs
• Target: All drugs targeting HER2 (trastuzumab and pertuzumab); microtubules (docetaxel); DNA (carboplatin)
• Manufacturer: Henan Cancer Hospital — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for HER2-positive breast cancer (metastatic or locally advanced)
• Also known as: TCbHP regimen group
• Compare: Docetaxel+ carboplatin+ trastuzumab + patuzumab vs similar drugs
• Pricing: Docetaxel+ carboplatin+ trastuzumab + patuzumab cost, discount & access